LUPIN gets nod to sell HIGH BLOOD-PRESSURE treatment tablets in CANADA

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a press-release submitted to the Indian Stock Exchanges, Mumbai headquartered pharma company Lupin Ltd said of having got nod from Canadian Pharma Regulator – Health Canada, to market tablets to treat high blood-pressure.

In a press-release as addressed to the Indian Bourses titled – “Lupin Receives Health Canada Approval for Propranolol Hydrochloride ER Capsules” it further read that, Pharma major Lupin Limited (Lupin) announced that it has received approval
for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada.

Lupin is the first generic company to receive an approval for generic Inderal®-LA Capsules for the Canadian market and the product has been approved and will be manufactured from Lupin’s Pithampur Unit-2 Facility.

Lupin’s Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of Inderal®-LA Capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.

Propranolol Hydrochloride Extended-Release (ER) Capsules (Canadian Reference Product: Inderal®-LA Capsules) had an annual sales of approximately CAD 8.6 million (MAT December 2018 IQVIA)


Follow DATELINE GUJARAT On :-

FacebookGoogle+LinkedinTwitterYouTube 


SHARE THIS NEWS ON :-